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Abstract: The purpose of this study was to investigate the expression of Yes-associated protein (YAP) in differ-
ent metastatic sites in metastatic breast cancer and to determine the clinical implications of these patterns. 
Immunohistochemical staining was used to investigate the expression of YAP and phospho-YAP in tissue microar-
rays from 122 cases of metastatic breast cancer (bone metastasis = 29, brain metastasis = 38, liver metastasis = 
12, and lung metastasis = 43). The expression levels of YAP and phospho-YAP differed according to the metastatic 
site in metastatic breast cancer. Specifically, nuclear expression of phospho-YAP was high in brain metastasis but 
low in lung metastasis (P = 0.010). The effects of YAP and phospho-YAP expression on clinical outcomes were inves-
tigated by univariate analysis. This analysis showed that nuclear YAP positivity (P = 0.008) and nuclear phospho-YAP 
positivity (P = 0.003) were both associated with shorter overall survival. In conclusion, the level of YAP expression 
varies according to the metastatic site in metastatic breast cancer. Moreover, high YAP expression was correlated 
with poor prognosis.
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Introduction
Yes-associated protein (YAP) has been report-
ed to play a role in controlling organ size by 
regulating cell proliferation and survival [1]. YAP 
is a transcriptional coactivator that regulates 
cellular responses in the nucleus by interacting 
with transcription factors. Kinase-mediated 
phosphorylation of YAP results in its sequestra-
tion from the nucleus to the cytoplasm, thereby 
downregulating the transcription of its target 
genes [2]. Recent studies have shown that YAP 
is associated with tumorigenesis; in breast can-
cer, YAP has been proposed to act as both a 
tumor suppressor and an oncogene. YAP has 
been proposed to act as a tumor suppressor 
because human breast cancer tissue exhibits 
decreased YAP expression compared with nor-
mal breast tissue [3]. Furthermore, knockdown 
of YAP in a breast cancer cell line suppressed 
anoikis, thereby resulting in increased cell 
migration and invasiveness. Tumor growth was 
also enhanced in a YAP-knockout mouse model 
[4]. In contrast, other studies suggested that 
YAP has an oncogenic role, since overexpres-
sion of YAP in a breast cancer cell line increased 
proliferation [5]. Moreover, YAP overexpression 
increased tumor formation and tumor growth in 
a study of mouse tumor xenografts [6].
Breast cancer is a cancer with high rates of 
morbidity and mortality, since it is prone to dis-
tant metastasis. The major metastatic sites of 
breast cancer are the lungs, brain, liver, and 
bone [7, 8]; most studies have focused on brain 
and bone metastasis [9-14]. The most common 
mechanism of tumor metastasis is reciprocal 
interaction between tumor cells and the host 
tissue. This interaction consists of a cycle of 
adhesion, proteolysis, invasion, and angiogen-
esis [8, 15]. However, since tumors show differ-
ent metastatic patterns, the seed and soil 
hypothesis has been proposed. This hypothesis 
states that a specific tumor (seed) can survive 
only in a specific visceral organ (soil) [16]. 
Metastatic breast cancers are known to exhibit 
characteristic findings according to the meta-
static site. Brain metastasis has been shown to 
be associated with young age, ER negativity, 
prior lung metastasis, HER-2 overexpression, 
EGFR overexpression, and basal subtype [11-
13], whereas bone metastasis has been shown 
to be associated with lower histologic grade, ER 
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positivity, ER positivity/PR negativity, the strand 
growth pattern, and the presence of fibrotic foci 
in the invasive ductal carcinoma [10, 17, 18]. As 
a result, specific metastatic sites are associat- 
ed with distinct characteristics in metastatic 
breast cancer. Therefore, the purpose of this 
study was to investigate the expression of YAP 
at different metastatic sites in metastatic 
breast cancer and to determine the clinical 
implications of these patterns.
Materials and methods
Patient selection
Cases with invasive primary breast cancer with 
metastasis to distant organs (liver, lungs, brain, 
and bone) were selected from the data files of 
the Department of Pathology of Severance 
Hospital, South Korea. Only patients with diag-
nosis of invasive ductal carcinoma were includ-
ed. This study was approved by the Institutional 
Review Board of our institution. A total of 122 
cases were included; 32 of these had samples 
of both the primary breast cancer tissue and 
the paired distant metastatic cancer tissue. All 
slides were reviewed again before analysis and 
their pathologic diagnoses were approved by 2 
different pathologists (JSK and WHJ). The histo-
logical grade of each sample was assessed 
using the Nottingham grading system [19].  
Tissue microarray
A representative area was selected on each 
H&E-stained tumor slide and a corresponding 
Table 1. Source, clone, and dilution of each antibody used in this study
Antibody Company Clone Dilution
YAP-related
    YAP Santa Cruz Biotechnology, Inc., California, USA 9A1 1:100
    Phospho-YAP (Ser127) Abcam, Cambridge, UK EP1675Y 1:100
Molecular subtype-related
    ER Thermo Scientific, San Diego, CA, USA SP1 1:100
    PR DAKO, Glostrup, Denmark PgR 1:50
    HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
    Ki-67 Abcam, Cambridge, UK MIB 1:1000
Table 2. Basal characteristics of patients with metastatic breast cancer
Parameter Totaln = 122 (%)
Bone metastasis
n = 29 (%)
Brain metastasis
n = 38 (%)
Liver metastasis
n = 12 (%)
Lung metastasis
n = 43 (%) P-value
Age (years) 0.045
    ≤50 61 (50.0) 18 (62.1) 17 (44.7) 2 (16.7) 24 (55.8)
    >50 61 (50.0) 11 (37.9) 21 (55.3) 10 (83.3) 19 (44.2)
ER <0.001
    Negative 59 (48.4) 7 (24.1) 25 (65.8) 2 (16.7) 25 (58.1)
    Positive 63 (51.6) 22 (75.9) 13 (34.2) 10 (83.3) 18 (41.9)
PR <0.001
    Negative 83 (68.0) 13 (44.8) 37 (97.4) 3 (25.0) 30 (69.8)
    Positive 39 (32.0) 16 (55.2) 1 (2.6) 9 (75.0) 13 (30.2)
HER-2 0.057
    Negative 81 (66.4) 22 (75.9) 19 (50.0) 10 (83.3) 30 (69.8)
    Positive 41 (33.6) 7 (24.1) 19 (50.0) 2 (16.7) 13 (30.2)
Molecular subtype <0.001
    Luminal A 44 (36.1) 19 (65.5) 4 (10.5) 8 (66.7) 13 (30.2)
    Luminal B 20 (16.4) 4 (13.8) 9 (23.7) 2 (16.7) 5 (11.6)
    HER-2 27 (22.1) 4 (13.8) 12 (31.6) 1 (8.3) 10 (23.3)
    TNBC 31 (25.4) 2 (6.9) 13 (34.2) 1 (8.3) 15 (34.9)
Patient death 41 (33.6) 17 (58.6) 11 (28.9) 5 (41.7) 8 (18.6) 0.004
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor-2; TNBC, triple negative breast 
cancer.
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spot was marked on the surface of the paraffin 
block. Using a biopsy needle, the selected area 
was punched out and a 3-mm tissue core was 
placed into a 6 × 5 recipient block. Tissue was 
Figure 1. Expression of YAP and phospho-YAP in metastatic breast cancer according to the metastatic site. The 
expression of nuclear phospho-YAP was higher in brain metastasis and lower in lung metastasis. Cytoplasmic YAP 
expression was higher in lung metastasis and lower in bone metastasis. Nuclear YAP expression was highest in bone 
metastasis. Stromal YAP and phospho-YAP expression were highest in bone metastasis.
Table 3. Expression of YAP and phospho-YAP according to the metastatic site in metastatic breast 
cancer 
Parameter Totaln = 122 (%)
Bone metastasis
n = 29 (%)
Brain metastasis
n = 38 (%)
Liver metastasis
n = 12 (%)
Lung metastasis
n = 43 (%) P-value
YAP (cytoplasmic) 0.075
    Negative 78 (63.9) 22 (75.9) 27 (71.1) 8 (66.7) 21 (48.8)
    Positive 44 (36.1) 7 (24.1) 11 (28.9) 4 (33.3) 22 (51.2)
YAP (nuclear) 0.067
    Negative 115 (94.3) 25 (86.2) 35 (92.1) 12 (100.0) 43 (100.0)
    Positive 7 (5.7) 4 (13.8) 3 (7.9) 0 (0.0) 0 (0.0)
Stromal YAP 0.017
    Negative 115 (94.3) 24 (82.8) 38 (100.0) 12 (100.0) 41 (95.3)
    Positive 7 (5.7) 5 (17.2) 0 (0.0) 0 (0.0) 2 (4.7)
pYAP (cytoplasmic) 0.280
    Negative 97 (79.5) 26 (89.7) 31 (81.6) 8 (66.7) 32 (74.4)
    Positive 25 (20.5) 3 (10.3) 7 (18.4) 4 (33.3) 11 (25.6)
pYAP (nuclear) 0.010
    Negative 108 (88.5) 25 (86.2) 29 (76.3) 11 (91.7) 43 (88.5)
    Positive 14 (11.5) 4 (13.8) 9 (23.7) 1 (8.3) 0 (0.0)
Stromal pYAP 0.089
    Negative 114 (93.4) 25 (86.2) 38 (100.0) 12 (100.0) 39 (90.7)
    Positive 8 (6.6) 4 (13.8) 0 (0.0) 0 (0.0) 4 (9.3)
YAP in metastatic breast cancer
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extracted from each invasive tumor. More than 
2 tissue cores were extracted from each tumor 
to minimize extraction bias. Each tissue core 
was assigned to a unique tissue microarray 
location number that was linked to a database 
containing other clinicopathologic data. 
Immunohistochemistry (IHC)
The antibodies used for IHC in this study are 
listed in Table 1. IHC staining was conducted 
using formalin-fixed, paraffin-embedded 3-μm 
thick tissue sections from all tissue microar-
Table 4. Correlation analysis of YAP and phospho-YAP expression according to tumor cell compart-
ment with primary and metastatic breast cancer according to metastatic site
Parameter 
Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis
N = 32 (%) P-value N = 7 (%) P-value n= 7 (%) P-value N = 2 (%) P-value N = 16 (%) P-value
YAP (cytoplasmic) 1.000 0.500 1.000 n/a 1.000
    (+) → (+) 4 (12.5) 0 (0.0) 1 (14.3) 0 (0.0) 3 (18.8)
    (+) → (-) 5 (15.6) 0 (0.0) 2 (28.6) 0 (0.0) 3 (18.8)
    (-) → (+) 6 (18.8) 2 (28.6) 1 (14.3) 0 (0.0) 3 (18.8)
    (-) → (-) 17 (53.1) 5 (71.4) 3 (42.9) 2 (100.0) 7 (43.8)
YAP (nuclear) 1.000 n/a 1.000 n/a n/a
    (+) → (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
    (+) → (-) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
    (-) → (+) 1 (3.1) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0)
    (-) → (-) 31 (96.9) 7 (100.0) 6 (85.7) 2 (100.0) 16 (100.0)
pYAP (cytoplasmic) 1.000 n/a 1.000 n/a 1.000
    (+) → (+) 2 (6.2) 0 (0.0) 1 (14.3) 0 (0.0) 1 (6.2)
    (+) → (-) 3 (9.4) 0 (0.0) 1 (14.3) 0 (0.0) 2 (12.5)
    (-) → (+) 2 (6.2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (12.5)
    (-) → (-) 25 (78.1) 7 (100.0) 5 (71.4) 2 (100.0) 11 (68.8)
pYAP (nuclear) 0.500 n/a 0.500 n/a n/a
    (+) → (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
    (+) → (-) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
    (-) → (+) 2 (6.2) 0 (0.0) 2 (28.6) 0 (0.0) 0 (0.0)
    (-) → (-) 30 (93.8) 7 (100.0) 5 (71.4) 2 (100.0) 16 (100.0)
Figure 2. Impacts of YAP and phospho-YAP expression on patient prognosis in metastatic breast cancer.
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Table 5. Univariate analysis of the impacts of YAP and phospho-YAP expression in metastatic breast cancer on overall survival by the log-rank 
test
Parameter
Total  
n = 122 (%)
Bone metastasis 
n = 29 (%)
Brain metastasis
n = 38 (%)
Liver metastasis 
n = 12 (%)
Lung metastasis 
n = 43 (%)
Mean survival, 
months
(95% CI) 
P-value
Mean survival, 
months
(95% CI) 
P-value
Mean survival, 
months
(95% CI) 
P-value
Mean survival, 
months
(95% CI) 
P-value
Mean survival, 
months
(95% CI) 
P-value
YAP (cytoplasmic) 0.624 0.432 0.873 0.501 0.415
    Negative 110 (92-128) 73 (47-98) 107 (81-133) 85 (59-110) 152 (125-178)
    Positive 120 (97-142) 86 (46-127) 74 (49-99) 57 (22-91) 125 (94-157)
YAP (nuclear) 0.008 0.205 0.198 n/a n/a
    Negative 120 (105-135) 88 (58-117) 112 (89-134) n/a n/a
    Positive 45 (24-66) 50 (21-79) 36 (13-60) n/a n/a
Stromal YAP 0.965 0.892 n/a n/a n/a
    Negative 114 (99-130) 79 (52-106) n/a n/a n/a
    Positive 55 (35-74) 48 (22-73) n/a n/a n/a
pYAP (cytoplasmic) 0.507 0.951 0.777 0.501 0.360
    Negative 111 (95-128) 79 (53-105) 108 (84-132) 85 (59-110) 135 (108-162)
    Positive 111 (89-134) 26 (7-45) 71 (39-102) 57 (22-91) 132 (110-154)
pYAP (nuclear) 0.003 0.205 0.028 n/a n/a
    Negative 123 (108-139) 88 (58-117) 126 (105-147) n/a n/a
    Positive 47 (34-60) 50 (21-79) 40 (28-51) n/a n/a
Stromal pYAP 0.267 0.645 n/a n/a n/a
    Negative 112 (97-128) 77 (51-103) n/a n/a n/a
    Positive 76 (57-95) 54 (25-84) n/a n/a n/a
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rays. Slides were deparaffinized and rehydrated 
using xylene and alcohol. A Ventana Discove- 
ry XT automated system (Ventana Medical 
System, Tucson, AZ, USA) was used for all stain-
ing. Appropriate positive and negative controls 
were included in each replicate. Antigen retri- 
eval was performed using CC1 buffer (Cell 
Conditioning 1; citrate buffer pH 6.0, Ventana 
Medical System). 
Interpretation of IHC results
A cut-off value of 1% or more positively stained 
nuclei was used to define ER and AR positivity 
[20]. HER-2 staining was used to classify each 
sample into one of the following categories, set 
by the American Society of Clinical Oncology 
(ASCO)/College of American Pathologists (CAP): 
0 = no immuntaining; 1+ = weak incomplete 
membranous staining, less than 10% of all 
tumor cells; 2+ = complete membranous stain-
ing, either uniform or weak in at least 10% of all 
tumor cells; and 3+ = uniform intense membra-
nous staining in at least 30% of all tumor cells 
[21]. HER-2 immunostaining was considered 
positive when strong (3+) membranous stain-
ing was observed. Cases with 0 to 1+ staining 
were regarded as HER-2-negative.
The final IHC staining results are expressed as 
the product of the proportion of stained cells 
and the immunostaining intensity. Stained cell 
proportions were scored as follows: 0, nega-
tive; 1, positive (less than 30% of all cells 
stained); and 2, positive (greater than or equal 
to 30% of all cells stained). The immunostain-
ing intensity was scored as follows: 0, negative; 
1, weak; 2, moderate; and 3, strong. A product 
between 0 and 1 was regarded as neg ative, 
between 2 and 4 as low posi tive, and between 
5 and 6 as high positive [22]. The Ki-67 labeling 
index (LI) was defined as the percentage of 
cells with nuclear expression out of all of the 
cancer cells.
Tumor phenotype classification
Breast cancer phenotypes were classified 
according to the ER, PR, HER-2 and Ki-67 IHC, 
and HER-2 FISH results as follows [23]: luminal 
A type: ER and/or PR positive, HER-2 negative, 
and Ki-67 LI < 14%; luminal B type: HER-2 neg-
ative-ER and/or PR positive, HER-2 negative, 
and Ki-67 LI ≥ 14%; HER-2 positive-ER and/or 
PR positive and HER-2 overexpressed and/or 
amplified; HER-2 type: ER and PR negative and 
HER-2 overexpressed and/or amplified; TNBC 
type: ER, PR, and HER-2 negative. 
Statistical analysis   
Data were analyzed using SPSS for Windows, 
version 12.0 (SPSS Inc., Chicago, IL, USA). 
Correlations of immunostaining results be- 
tween primary breast cancer and metastatic 
breast cancer were analyzed by McNemar’s 
test. Student’s t-test and Fisher’s exact test 
were used to evaluate the significance of differ-
ences in continuous and categorical variables, 
respectively. Corrected p-values and the Bon- 
ferroni method were used for multiple compari-
sons. Statistical significance was assumed 
when P < 0.05. Kaplan-Meier survival curves 
and log-rank statistics were employed to evalu-
ate time to tumor metastasis and time to 
survival. 
Results 
Basal characteristics of patients with meta-
static breast cancer
Among the 122 patients in this study, 43 
(35.2%) had lung metastases, 38 (31.1%) had 
brain metastases, 29 (23.8%) had bone metas-
tases, and 12 (9.8%) had liver metastases. The 
proportions of ER positivity and PR positivity 
were higher in bone metastasis and liver 
metastasis (P < 0.001). The proportions of lu- 
minal A type were higher in bone and liver 
metastasis, whereas the proportions of TNBC 
were higher in brain and lung metastasis (P < 
0.001) (Table 2).
Expression of YAP and phospho-YAP accord-
ing to the metastatic site of metastatic breast 
cancer 
We next analyzed the patterns of YAP and phos-
pho-YAP expression observed at different met-
astatic sites. YAP and phospho-YAP both exhib-
ited nuclear and/or cytoplasmic expression in 
tumor cells, whereas they were exclusively cyto-
plasmic in stromal tissue (Figure 1). Moreover, 
the pattern of nuclear phospho-YAP expression 
varied according to the metastatic site. Spe- 
cifically, nuclear phospho-YAP exhibited higher 
expression in brain metastasis and lower ex- 
pression in lung metastasis (P = 0.010). The 
level of YAP expression also showed different 
YAP in metastatic breast cancer
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tendencies according to the subcellular local-
ization of YAP; for instance, cytoplasmic YAP 
expression was higher in lung metastasis and 
lower in bone metastasis (P = 0.075). Nuclear 
YAP expression was higher in bone metastasis, 
whereas nuclear YAP was not observed in lung 
or liver metastasis (P = 0.067). The level of 
stromal YAP expression also varied according 
to the metastatic site; stromal YAP expression 
was higher in bone metastasis, whereas stro-
mal YAP was not expressed in brain or liver 
metastasis (P = 0.017) (Figure 1 and Table 3).
Correlations of YAP and phospho-YAP expres-
sion levels with primary and metastatic breast 
cancer according to metastatic site
We analyzed the expression of YAP and phos-
pho-YAP in primary and metastatic cancers in 
49 paired cases with both primary and distant 
metastatic cancer tissue. No significant differ-
ences were observed regarding the expression 
of YAP or phospho-YAP (Table 4). 
Impact of YAP and phospho-YAP expression on 
patient prognosis
The impacts of YAP expression and phospho-
YAP expression on clinical outcomes were in- 
vestigated by univariate analysis. This analysis 
revealed that nuclear YAP positivity (P = 0.008) 
and nuclear phospho-YAP positivity (P = 0.003) 
were significantly associated with shorter over-
all survival (Figure 2 and Table 5).  
Discussion
The purpose of this study was to investigate the 
expression of YAP in different metastatic sites 
in metastatic breast cancer. Previous studies 
reported that YAP is expressed in 75% [6] and 
45% [3] of all breast cancers. The subcellular 
localization of YAP also differs; nuclear YAP 
expression was observed in 6.2-26.5% and 
cytoplasmic YAP expression was observed in 
4.7-15% of all patients with breast cancer [3, 
25]. Kinase-mediated phosphorylation of YAP 
results in its sequestration from the nucleus to 
cytoplasm, meaning that it accumulates in the 
nucleus (where we observed YAP). Therefore, in 
theory, IHC staining of YAP should reveal nucle-
ar expression and phospho-YAP cytoplasmic 
expression. However, in this study, IHC staining 
of YAP demonstrated cytoplasmic expression 
and phospho-YAP nuclear expression. Our 
results are consistent with those of a previous 
study that reported nuclear and cytoplasmic 
expression of YAP in breast cancer [24]. 
We found that YAP expression varied according 
to the metastatic site. The expression levels of 
nuclear YAP and phospho-YAP were higher in 
bone and brain metastasis, whereas the ex- 
pression levels of cytoplasmic YAP and phos-
pho-YAP were higher in liver and lung metasta-
sis. These metastatic site-specific differences 
in YAP expression have several potential expla-
nations. First, these differences may reflect dif-
ferent cancer cell characteristics. In breast 
cancer, YAP expression has been reported to 
be related with ER, PR, and HER-2 positivity [3, 
25], all of which are known to be relevant to 
tumor biology. Metastatic breast cancer is 
known to exhibit distinct tumor biology accord-
ing to the metastatic site; for instance, brain 
metastasis exhibits ER negativity, HER-2 over-
expression, EGFR overexpression, and the 
basal subtype [11-13]. In contrast, bone metas-
tasis exhibits lower histologic grade, ER positiv-
ity, and PR negativity [10, 17, 18]. As a result, 
these distinct cancer cell characteristics of the 
various metastatic sites may influence YAP ex- 
pression. Another possible mechanism is mic- 
roenvironment differences at the metastatic 
site. For instance, YAP has been reported to be 
involved in the cancer - stroma interaction. The 
actin cytoskeleton might reduce the phosphor-
ylation of YAP, which is a key molecule in the 
Hippo signaling pathway, thereby stimulating 
nuclear translocation of activated YAP. This 
translocation could in turn drive the expression 
of downstream CCN growth factors, such as 
CCN1/CYR61 and CCN2/CTGF [26, 27]. These 
factors could create different microenviron-
ments at each metastatic site, thus resulting in 
different levels of YAP expression. 
Cancer-associated fibroblasts (CAFs) are an 
essential factor in the stromal cellular compo-
nent of breast cancer. Although CAFs consist of 
several different groups of cells, α-smooth 
muscle actin-expressing myofibroblasts have 
been shown to be the most important compo-
nent [28]. CAFs may play a role in YAP expres-
sion and regulation. In primary breast cancer, 
YAP has been reported to be expressed both in 
tumors and in stroma [25]; we observed YAP 
stromal expression in 5-6% of all samples. In 
addition, different CAF phenotypes have been 
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reported to be associated with different histo-
logical and molecular stroma subtypes [29]. 
Different CAF phenotypes might be associated 
with different metastatic sites, a finding that 
would support a role for YAP expression in met-
astatic breast cancer.
In this study, nuclear YAP positivity and nuclear 
phospho-YAP positivity were both associated 
with shorter overall survival. Our results are 
consistent with previous studies reporting that 
YAP expression is linked with poor prognosis in 
ovarian cancer [30], urinary bladder cancer 
[31], colorectal cancer [32], esophageal cancer 
[33], stomach cancer [34], and lung cancer 
[35]. Our results indicate that YAP might be a 
potential treatment target in metastatic breast 
cancer. The efficacy of targeting YAP in various 
carcinomas has been demonstrated in one 
study in which targeting YAP inhibited cancer 
proliferation [36]. Further studies are required 
to substantiate this hypothesis.
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